上 海 君 实 生 物 医 药 科 技 股 份 有 限 公 司 董 事 会 合 规 委 员 会 工 作 细 则 | | | | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 人员组成 | 1 | | 第三章 | 职责权限 | 1 | | 第四章 | 议事规则 | 2 | | 第五章 | 附则 | 3 | 上海君实生物医药科技股份有限公司 董事会合规委员会工作细则 第四条 合规委员会委员由董事长或三分之一以上董事会成员或董事会提 名委员会提名，并由董事会以全体董事过半数选举产生。 第五条 合规委员会设召集人即主任委员一名，负责主持委员会工作。主 任委员不能或不履行职责时，由二分之一以上委员共同推举一名委员代行其职责。 第六条 合规委员会任期与董事会任期一致，委员任期届满，连选可以连 任。期间如有委员不再担任公司董事职务，自动失去委员资格。合规委员会委员 可以在任期届满以前向董事会提交书面辞职报告，辞去委员职务。合规委员会委 员在失去资格或获准辞职后，由董事会根据相关法律、法规、规范性文件及上述 第三至第五条的规定补足委员人数。 第三章 职责权限 第一章 总则 第一条 为进 ...

上海君实生物医药科技股份有限公司2025 年半年度报告 公司代码：688180 公司简称：君实生物 上海君实生物医药科技股份有限公司 2025 年半年度报告 1 / 208 上海君实生物医药科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 生物医药行业具有研发周期长、投入大、风险高的特点。公司在报告期内不断丰富产品管线， 持续探索药物的联合治疗，快速推进现有临床项目的开展和储备研发项目的开发，营业收入尚不 能覆盖研发费用及其他开支，报告期内公司尚未实现盈利。 报告期内，公司在创新药物的发现、研发、生产和商业化等方面皆有源头创新性、突破性进 展，现金流情况良好，公司核心管理层及研发团队稳定。随着更多在研产品逐步实现商业化以及 已上市产品更多适应症的拓展，公司的持续经营能力将不断提升。 公司致力于创新疗法的发现、开发和商业化。公司积极布局覆盖多项疾病治疗领域的在研产 品管线，未来仍将维持相应规模的研发投入用于在研产品的临床前研究、 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-040 上海君实生物医药科技股份有限公司 2025 年半年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司募集 资金监管规则》《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》和《上海证券交易所科创板股票上市规则》等相关规定，上海君实生物医 药科技股份有限公司（以下简称"公司"）董事会将公司2025年半年度（以下简 称"报告期"）募集资金存放与实际使用情况专项说明如下： 根据中国证监会于2020年5月20日出具的《关于同意上海君实生物医药科技 股份有限公司首次公开发行股票注册的批复》（证监许可〔2020〕940号），公 司获准向社会公开发行人民币普通股87,130,000股，每股发行价格为人民币55.50 元，募集资金总额为人民币4,835,715,000.00元；扣除不含税发行费用人民币 338,736,673.27元，实际募集资金净额为人民 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-041 上海君实生物医药科技股份有限公司 关于变更注册资本、取消监事会并修订《公司章程》及 其附件、修订及制定部分内部管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第四届董事会第十次会议，审议通过了《关于变更注册资本、取消监 事会、修订<公司章程>及其附件的议案》《关于修订及制定部分内部管理制度 的议案》，同日，公司召开第四届监事会第八次会议，审议通过了《关于取消监 事会、废止<监事会议事规则>的议案》。现将有关事项公告如下： 一、变更注册资本相关情况 2025 年 6 月 20 日，公司完成根据一般授权配售新 H 股，按每股 H 股 25.35 港元的配售价格向符合条件的承配人成功配售合计 41,000,000 股 H 股配售股份。 本次配售完成后，公司总股本由 985,689,871 股增加至 1,026,689,871 股，其中 A 股总股本为 ...

上海君实生物医药科技股份有限公司 2025 年度"提质增效重回报"行动方案的 半年度评估报告 为进一步履行社会责任，全方位推动公司经营的持续优化与升级，上海君实 生物医药科技股份有限公司（以下简称"公司"）结合自身发展战略和经营情况， 制定了《上海君实生物医药科技股份有限公司 2025 年度"提质增效重回报"行 动方案》（以下简称"2025 年行动方案"或"本方案"），详细情况参见公司已于 2025 年 3 月 28 日披露于上海证券交易所网站（www.sse.com.cn）的公告。2025 年上半年，公司切实履行并持续评估 2025 年行动方案的具体举措，现将 2025 年行动方案在 2025 年半年度（以下简称"报告期"）内的实施和效果评估情况报 告如下： 一、提升经营效率，加强合规建设，促进高质量发展 公司具备完整的从创新药物的发现和开发、在全球范围内的临床研究、大规 模生产到商业化的全产业链能力，旨在成为立足中国、布局全球的创新医药公司。 公司坚持质量为本、求真务实、诚信合规、追求卓越的企业价值观，致力于通过 源头创新以及合作开发等形式来研发 first-in-class（同类首创）或 best-in ...

Group 1 - The core viewpoint of the article highlights that Junshi Biosciences reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders of the listed company was 413 million yuan, an improvement from a net loss of 645 million yuan in the same period last year [1] - Research and development expenses accounted for 60.39% of the revenue, which is a decrease of 9.12 percentage points compared to the previous year [1]

Market Overview - The Hong Kong stock market failed to maintain its strong performance from the previous day, with all three major indices experiencing a collective adjustment. The Hang Seng Index fell by 1.18% or 304.99 points, closing at 25,524.92 points, with a total trading volume of HKD 31.78 billion. The Hang Seng China Enterprises Index decreased by 1.07% to 9,148.66 points, while the Hang Seng Tech Index dropped by 0.74% to 5,782.24 points [1] Blue-Chip Stocks Performance - CSPC Pharmaceutical Group (01093) led the decline among blue-chip stocks, falling by 4.33% to HKD 10.38, with a trading volume of HKD 1.797 billion, contributing a loss of 6.04 points to the Hang Seng Index. Bank of America Securities reported a 14.3% year-on-year decline in total revenue for CSPC in Q2, with attributable net profit down 24% to RMB 1.1 billion. The firm revised its revenue forecasts for 2025 to 2027 down by 25%, 2%, and 11% respectively [2] Sector Highlights - Large technology stocks mostly declined, with Alibaba down 2.57% and Tencent down 0.81%. Gold stocks surged, with China Gold International rising over 10%. Apple is expected to initiate a three-year innovation cycle, boosting related stocks like Lens Technology, which rose over 5%. Gaming stocks and some new consumption concepts performed well, with Melco International Development up over 9% [3][5] Federal Reserve Insights - Federal Reserve Chairman Jerome Powell indicated rising downside risks in the U.S. labor market, suggesting a potential policy adjustment could be appropriate. This statement is seen as a strong signal for a possible interest rate cut as early as September. The market reacted positively, particularly for precious metals, with expectations for further increases in gold prices [4] Gaming Sector Performance - The gaming sector continued its upward trend, with Melco International Development rising 9.27% to HKD 5.54. According to JPMorgan, Macau's gaming revenue for the first 24 days of August reached MOP 17.65 billion, with a daily average of MOP 735 million, reflecting a 9% increase from the previous week [6] Pharmaceutical Sector Challenges - The pharmaceutical sector faced pressure, with several stocks declining. Notably, CStone Pharmaceuticals (09966) fell 6.74% to HKD 10.24. U.S. President Trump's announcement to drastically reduce drug prices could create significant challenges for the global pharmaceutical industry, presenting both opportunities and risks for Chinese biotech stocks [6] Notable Stock Movements - Double Ended Co. (06960) debuted with a 31.29% increase, closing at HKD 19.05. The company focuses on energy storage solutions in the data and communication sectors, with a projected market share of 11.1% by 2024 [7] - Kingsoft Holdings (03918) reached a new high, rising 17.94% to HKD 5.72, reporting a 16.76% year-on-year revenue increase to USD 342 million [8] - Angelalign Technology (06699) saw a 10.28% increase to HKD 75.1, with a 33.1% year-on-year revenue growth reported [9] - Meitu Inc. (01357) rose 7.9% to HKD 11.47 after being included in the MSCI China Index, with Morgan Stanley expressing confidence in its long-term growth potential [10] - Xintai Medical (02291) experienced a significant drop of 12.75% to HKD 23.96 following a major shareholder's sale of shares [11]

| 指数 | 最新 | 涨跌幅 | | --- | --- | --- | | 相生指数 | 25524.92 | -1.18% | | 国企指数 | 9148.66 | -1.07% | | 红筹指数 | 4343.85 | -1.02% | 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯：北京时间8月26日16:00，恒生指数收盘下跌304.99点，跌幅为1.18%，报收25524.92点；国 企指数收盘下跌99.34点，跌幅为1.07%，报收9148.66点；红筹指数收盘下跌44.65点，跌幅为1.02%，报 收4343.85点。南向资金当日净流入165.73亿港元。东方甄选跌超11%，蔚来、君实生物跌超6%，中兴 通讯跌近6%，碧桂园跌超5%；中国黄金国际涨超10%，灵宝黄金涨超9%。 （记者 胡玲） ...

Group 1 - The core viewpoint of the article highlights a significant decline in Hong Kong's biopharmaceutical stocks, with notable drops in several companies [2] Group 2 - Junshi Biosciences and Kelun Pharmaceutical both experienced declines exceeding 7% [2] - Innovent Biologics saw a drop of over 4% [2] - WuXi AppTec, Tigermed, and CanSino Biologics all fell by more than 3% [2]

Group 1 - The core viewpoint of the article highlights the overall poor performance of Hong Kong's biopharmaceutical stocks, with significant declines in major companies such as WuXi AppTec, Tigermed, and King’s Ray Biotech [1] - U.S. President Trump announced plans to reduce drug prices to 1/1400 to 1/1500 of current prices and to impose tariffs on pharmaceuticals, which could create volatility in the global pharmaceutical industry [1] - The Chinese biopharmaceutical sector faces both opportunities and challenges due to these developments, with potential short-term market fluctuations driven by uncertainty, particularly for businesses exposed to the U.S. market [1] Group 2 - In the long term, China's pharmaceutical industry may leverage its innovation and supply chain advantages to find new growth opportunities in the global pharmaceutical landscape, especially in areas like CDMO and internationalization of innovative drugs [1] - The article lists the latest prices and percentage changes for various biopharmaceutical stocks, indicating a general downward trend across the sector [1]